Literature DB >> 15785318

NOD2 variants and the risk of malignant melanoma.

T Debniak1, G Kurzawski, T Huzarski, T Byrski, J Gronwald, B Debniak, A Rozmiarek, I Dziuba, E Złowocka, J Suchy, B Górski, C Cybulski, M Mierzejewski, B Masojć, K Medrek, O Oszurek, J Lubiński.   

Abstract

Both hereditary and environmental factors are important in the aetiology of malignant melanoma. Among the risk factors for malignant melanoma are immunodeficiency and immunosuppression. The recently identified NOD2 gene is involved in the regulation of immune function through activation of the transcription factor nuclear factor-kappaB (NF-kappaB). Three common NOD2 mutations -- 3020insC, G908R and R702W -- have been shown to be associated with chronic inflammatory disease such as Crohn's disease, the 3020insC also with human malignancy colorectal cancer. We examined the frequency of the NOD2 variants in 424 patients with malignant melanoma and 649 controls. The 3020insC mutation was present in 6.9% of unselected cases and 7% of the controls (odds ratio (OR) 1.0; P not significant). The mutation was present in 6.8% of 162 cases diagnosed under the age of 50 and in 7.1% of cases diagnosed after the age of 50. A mutation was present in the index case in 5% of 40 familial melanomas (OR 0.7; P not significant). There were no statistically significant differences between prevalence of G908R and R702W in malignant melanoma patients and controls. In conclusion, the three common NOD2 mutations are not associated with increased risk of development of malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15785318     DOI: 10.1097/00008469-200504000-00010

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  5 in total

Review 1.  Unleashing the therapeutic potential of NOD-like receptors.

Authors:  Kaoru Geddes; João G Magalhães; Stephen E Girardin
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

2.  Bladder cancer survival in patients with NOD2 or CDKN2A variants.

Authors:  Elżbieta Złowocka-Perłowska; Thierry van de Wetering; Aleksandra Tołoczko-Grabarek; Rodney J Scott; Jan Lubiński
Journal:  Oncotarget       Date:  2022-04-22

3.  The NOD2 3020insC Mutation in Women with Breast Cancer from the Bydgoszcz Region in Poland. First Results.

Authors:  Hanna Janiszewska; Olga Haus; Anna Lauda-Swieciak; Aneta Bak; Tomasz Mierzwa; Jan Sir; Ryszard Laskowski
Journal:  Hered Cancer Clin Pract       Date:  2006-01-15       Impact factor: 2.857

4.  Expression of Autoimmunity-Related Genes in Melanoma.

Authors:  Francesca Scatozza; Antonio Facchiano
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

5.  NOD2 polymorphisms associated with cancer risk: a meta-analysis.

Authors:  Jingwei Liu; Caiyun He; Qian Xu; Chengzhong Xing; Yuan Yuan
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.